Recent Analysts’ Ratings Updates for Legend Biotech (LEGN)

Legend Biotech (NASDAQ: LEGN) recently received a number of ratings updates from brokerages and research firms:

• 7/28/2026 – Legend Biotech had its “buy” rating reaffirmed by Benchmark Co..
• 7/28/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 7/27/2026 – Legend Biotech had its “neutral” rating reaffirmed by UBS Group AG. They now have a $28.00 price target on the stock, down from $49.00.
• 7/27/2026 – Legend Biotech had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $58.00 price target on the stock.
• 7/27/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $63.00 to $59.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – Legend Biotech was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $28.00 price target on the stock, down from $49.00.
• 7/16/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright.
• 7/13/2026 – Legend Biotech is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $35.00 price target on the stock.
• 7/10/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/7/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $64.00 to $63.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/3/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/3/2026 – Legend Biotech had its price target raised by UBS Group AG from $31.00 to $49.00. They now have a “buy” rating on the stock.
• 6/3/2026 – Legend Biotech had its price target raised by HC Wainwright from $50.00 to $65.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Legend Biotech had its price target raised by UBS Group AG from $31.00 to $50.00. They now have a “buy” rating on the stock.

Insider Transactions at Legend Biotech

In other news, CEO Ying Huang sold 5,566 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the transaction, the chief executive officer owned 241,872 shares of the company’s stock, valued at approximately $3,574,868.16. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.02% of the company’s stock.

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.